JPRN-jRCT2011230016招募中3 期
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Ishibashi Hideyasu0 个研究点目标入组 50 人开始时间: 2023年7月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Has untreated pathologically confirmed colon adenocarcinoma
- •-Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III
- •-Has radiologically evaluable disease
- •-Has a tumor demonstrating the presence of either dMMR status or MSI-H
排除标准
- •-Has distant metastatic disease.
- •-Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of colon cancer
- •-Has a tumor that, in the investigator's judgment is causing symptomatic bowel obstruction or otherwise requires urgent/emergent surgery
- •-Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to enrollment
- •-Has any history of interstitial lung disease or pneumonitis
- •-Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice
- •-Has a history of allogenic stem cell transplantation or organ transplantation
- •-Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention
- •-Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study
- •-Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of FOLFOX or CAPEOX
研究者
相似试验
招募中
1 期
Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancerParticipants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2MedDRA version: 20.0Level: PTClassification code: 10001167Term: Adenocarcinoma of colon Class: 100000004864MedDRA version: 20.0Level: HLTClassification code: 10010023Term: Colorectal neoplasms malignant Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10017991Term: Gastrointestinal neoplasms malignant and unspecified Class: 10029104CTIS2023-503265-27-00Glaxosmithkline Research & Development Limited710
进行中（未招募）
1 期
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal CancerMetastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004285-35-PLBristol-Myers Squibb International Corporation700
招募中
3 期
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal CancerColorectal CancerNL-OMON53835Bristol-Myers Squibb24
招募中
1 期
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal CancerCTIS2023-503797-21-00Bristol Myers Squibb International Corporation683
进行中（未招募）
1 期
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal CancerEUCTR2021-004285-35-ATBristol-Myers Squibb International Corporation700